COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort

Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated with worse prognosis. The aim of this study was to investigate the epidemiology, risk factors and outcomes of AKI in patients with COVID-19 in a large UK tertiary centre. We analysed data of consecutive adul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC nephrology 2021-11, Vol.22 (1), p.359-359, Article 359
Hauptverfasser: Jewell, Paul D, Bramham, Kate, Galloway, James, Post, Frank, Norton, Sam, Teo, James, Fisher, Richard, Saha, Rohit, Hutchings, Sam, Hopkins, Phil, Smith, Priscilla, Joslin, Jennifer, Jayawardene, Satish, Mackie, Sarah, Mudhaffer, Ali, Holloway, Amelia, Kibble, Henry, Akter, Mosammat, Zuckerman, Benjamin, Palmer, Kieran, Murphy, Ciara, Iatropoulou, Domniki, Sharpe, Claire C, Lioudaki, Eirini
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Acute kidney injury (AKI) is common among patients hospitalised with COVID-19 and associated with worse prognosis. The aim of this study was to investigate the epidemiology, risk factors and outcomes of AKI in patients with COVID-19 in a large UK tertiary centre. We analysed data of consecutive adults admitted with a laboratory-confirmed diagnosis of COVID-19 across two sites of a hospital in London, UK, from 1st January to 13th May 2020. Of the 1248 inpatients included, 487 (39%) experienced AKI (51% stage 1, 13% stage 2, and 36% stage 3). The weekly AKI incidence rate gradually increased to peak at week 5 (3.12 cases/100 patient-days), before reducing to its nadir (0.83 cases/100 patient-days) at the end the study period (week 10). Among AKI survivors, 84.0% had recovered renal function to pre-admission levels before discharge and none required on-going renal replacement therapy (RRT). Pre-existing renal impairment [odds ratio (OR) 3.05, 95%CI 2.24-4,18; p 
ISSN:1471-2369
1471-2369
DOI:10.1186/s12882-021-02557-x